This is a Phase 1b, dose escalation study of the investigational agent, CRLX101, given in
combination with Bevacizumab in patients with advanced renal cell carcinoma. The purpose of
this study is to determine the initial safety and effectiveness of this agent in combination
with Bevacizumab. The investigators are also trying to determine the best dose level of
CRLX101 to give in combination with bevacizumab. About 22 subjects will be enrolled in this
study at the University of Pennsylvania.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania